Background: The nuclear factor-kappa B activation in mucosa-associated lymphoid tissue (MALT) lymphoma pathogenesis provided the rationale for the evaluation of bortezomib in this malignancy.
introduction
Extranodal marginal zone B-cell lymphoma, also defined as mucosa-associated lymphoid tissue (MALT) lymphoma, represents the third entity in terms of incidence among lymphoid neoplasms in Western countries [1] . MALT lymphoma usually has an indolent course, with a 5-year survival ranging from 80% up to 95%, but with relatively short progression-free survival rates, particularly for patients presenting with advanced stage or unfavorable International Prognostic Index (IPI) [2, 3] .
The eradication of Helicobacter pylori with antibiotics is considered safe and active as the sole initial treatment in localized gastric MALT lymphoma [2] . Some evidence supports the antitumor activity of antibiotic therapy directed against Chlamydophila psittaci infection in primary orbital lymphoma and against other microorganisms in other rare locations [4] . However, it is still unknown whether antibiotics will definitively cure the lymphoma.
For the patients who fail to respond to antibiotics and for non-infection-related or disseminated disease, the therapeutic choice includes conventional oncological modalities such as antibody therapy, chemotherapy, radiotherapy, and surgery, alone or in combination [5] [6] [7] [8] [9] [10] [11] . Unfortunately, few studies, in most cases with nonrandomized design, addressed the problem. Therefore, optimal therapy for MALT lymphomas remains to be determined and new systemic treatment strategies should be investigated [2] .
During the last decade, a number of studies demonstrated clinical efficacy of the proteasome inhibitor bortezomib in multiple myeloma and other hematologic original article *Correspondence to: Dr. A. Conconi, International Extranodal Lymphoma Study Group Operation Office, Ospedale San Giovanni, 6500 Bellinzona, Switzerland. Tel: +41-91-8119040; Fax: +41-91-8119182; E-mail: conconi@med.unipmn.it malignancies [12] [13] [14] . Evidence of significant antitumor activity was reported in different subsets of non-Hodgkin's lymphomas including both indolent and aggressive entities [15] [16] [17] [18] [19] [20] [21] [22] . Different molecular mechanisms of action were claimed for bortezomib including cell-cycle deregulation, direct induction of apoptosis, and negative regulation of the nuclear factor-kappa B (NF-jB) activity [23] [24] [25] . The constitutive activation of NF-jB in MALT lymphomas-which represents the common final molecular pathway of the most frequent genetic lesions associated with the disease [26, 27] -provides a sound rationale for clinical investigations of bortezomib in this clinical setting along with the clinical activity of the drug in several lymphoid neoplasms [13, 14] . The present study, coordinated by the International Extranodal Lymphoma Study Group (IELSG), assessed the antitumor activity of bortezomib, as single agent, in MALT lymphoma patients relapsed or refractory after prior systemic therapy including either chemotherapy or immunotherapy with rituximab.
materials and methods

study design and end points
The primary objective of this nonrandomized phase II study was to assess the overall response rate (ORR) to bortezomib in MALT lymphoma patients. The secondary objective was to assess the toxicity profile of bortezomib in this population. The sample size was based on the primary end point of ORR. The number of patients required was therefore calculated on the assumption that a response rate of at least 40% would be sufficient to consider active experimental therapy. Accordingly, up to 33 patients were required to provide a single-arm study with 80% power at an overall 5% significance level [28] .
study sites
The trial was conducted between March 2005 and April 2009 at 10 centers in Italy, Spain, and Switzerland and was carried out according to the principles of the Declaration of Helsinki with its current amendments. All patients gave written informed consent. The protocol and informedconsent forms were approved by the local institutional review boards and ethics committees of each participating institution. This study is registered with ClinicalTrial.gov, number NCT00210327.
patient population and pretreatment evaluation
Patients were eligible if they were >18 years of age and had biopsy-proven extranodal marginal zone B- /l), unless due to lymphoma involvement. Patients with a positive serological test for the human immunodeficiency virus were also excluded. All patients were clinically staged according to the Ann Arbor criteria and underwent staging procedures including history; physical examination; complete blood counts; chemistry profile; computerized tomography of the chest, abdomen, and pelvis; and bone marrow aspiration/biopsy within the 4 weeks before treatment. Magnetic resonance imaging of the orbit was carried out if clinically required. Endoscopic investigations with multiple mucosal biopsies were carried out in case of gastric lymphoma involvement. The IPI was used to determine the prognostic risk [30] . followed by a 1-week rest period (one cycle); patients were treated for up to a total of six cycles. All cycles were delivered on an outpatient basis. Treatment was discontinued on withdrawal of the patient's consent, disease progression, or the occurrence of unacceptable toxic effects. Growthstimulating factors were not routinely administered to prevent neutropenia, but patients who experienced grade 3 or 4 neutropenia or developed neutropenic fever between cycles might have received growth factors for subsequent cycles of therapy, at the physician's discretion. No specific recommendation was done for antiviral prophylaxis.
assessment of toxicity
Patients who received at least one dose of bortezomib were included in the analysis of toxicity evaluated and graded according to NCI-Common Toxicity Criteria Toxicity (version 3) [31] . Neuropathic pain and peripheral sensory neuropathy were managed with the use of established dosemodification guidelines [32] .
assessment of response
Patients were assessed for response after two and six courses of therapy.
Restaging included a repeat of all previously abnormal staging tests. Tumor responses were classified as CR, PR, stable disease (SD), or relapsing/ progressive disease according to the NCI standardized response criteria for non-Hodgkin's lymphomas. ORR was defined as the sum of CR and PR rates [29] . For primary gastric localizations, definition of response was based on endoscopic and histological findings after extensive sampling through the gastric mucosa and defined according to the Groupe d'Etude des Lymphomes de l'Adulte (GELA) histological grading system for posttreatment evaluation [33] .
statistical considerations
Statistical analysis was conducted using the STATA 5.0 software package (Stata Statistical Software: Release 5.0; Stata Corporation 1997, College Station, TX). The median follow-up was computed by the reverse KaplanMeier method [34] . Response duration and time to treatment failure were defined according to the NCI criteria [29] . Response duration was calculated from the date of achievement of the best response to the date of relapse/ progression or last follow-up; progression-free survival was calculated from the date of trial registration to the date of disease progression or death from any cause or last follow-up. Survival probabilities were calculated using the life table method and survival curves were estimated by the method of Kaplan-Meier [35] and reported with 95% Greenwood's confidence intervals (95% CIs); survival differences between patient groups were evaluated using the log-rank test [36] . Binomial exact 95% CIs were calculated for remission rates. Associations in two-way tables were tested for statistical significance using the Fisher's exact test (two tailed response to bortezomib therapy and outcome
Among the 32 patients enrolled, 3 patients were not evaluated for response. One patient withdrew his consent before treatment start. One patient experienced an ischemic stroke after a single course of therapy. One patient, who received prior chlorambucil therapy, had a diagnosis of acute myeloid leukemia immediately after the completion of the first course of study treatment. Fourteen (48%; 95% CI 29% to 67%) of the 29 assessable patients had objective responses with nine CRs (31%; 95% CI 15% to 51%) and five PRs (17%; 95% CI 6% to 36%). Responses were observed either in gastric and non-gastric MALT lymphomas (Table 2 ). In six cases achieving objective response (five CR and one PR), patients were reported as resistant to last prior therapy; in two other refractory patients, a stabilization of disease was reported ( Table 3 ). The median time to best response was 3 months (range, 1-16 months). Whereas in nine patients (31%; 95% CI 15% to 51%) SD was observed, six patients (21%; 95% CI 8% to 40%) experienced a disease progression.
After a median follow-up of 24 months (range, 5-47 months), 4 of the 14 responding patients experienced relapse: two after a CR and two after a PR. Three of the nine patients in whom an SD was documented after the study treatment experienced a disease progression. No significant difference in the duration of response was seen between the patients achieving a CR and those achieving a PR (58% of CRs and 56% of PRs have not yet relapsed at 4 years). The median response duration was not reached (Figure 1 ). Five patients died: two died of disease progression (after the diagnosis of a gastric cancer in one case), one patient died of liver failure, which occurred in the context of hepatitis C virusrelated chronic hepatopathy, 5 months after a single cycle of study treatment early interrupted after disease progression with no evidence of toxicity. In one patient, a diagnosis of acute myeloid leukemia was carried out on a bone marrow biopsy whose result was not available at time of treatment start, when the patient had normal blood counts. A fifth patient died of unknown causes 11 months after a single cycle of study treatment interrupted due to ischemic stroke (Table 4) .
Among the 31 patients who received at least one cycle of study treatment, median progression-free survival was 25 months (range, 1-47 months) (Figure 2 ).
prognostic factors
Despite the small number of patients, several variables-including sex, age, stage, tumor burden, performance status, lactate dehydrogenase and b2-microglobulin serum level, IPI, B-symptoms, previous treatment, and bone marrow involvement-were analyzed for their possible association with response, with no significant result. A trend toward an higher probability of response was observed for patients receiving at least three cycles of therapy (P = 0.08).
toxicity
The adverse events observed in the 132 courses analyzed for toxicity are reported in Table 5 . The majority of these events were of mild to moderate severity and most of them were reversible. A relevant proportion of patients experienced neurological side-effects (20 patients, 65%; 95% CI 45% to 81%) in terms of peripheral sensory neuropathy, neuropathic pain, and orthostatic hypotension; these manifestations represented main cause of dose reduction and early treatment discontinuation (see above in 'Treatment' section). No toxicityrelated deaths were observed.
discussion
The relevant pathogenetic role of the constitutive activation of NF-jB in MALT lymphomas provides the biologic rationale for this phase II study. Indeed, the anti-lymphoma mechanism of action of bortezomib (different from that of either the classical chemotherapeutic agents or the currently used monoclonal antibodies and leading to a potent inhibition of NF-jB) strongly supported exploring its clinical activity.
Though bortezomib has been recently shown to be active in untreated patients with MALT lymphomas [37] , its toxicity seems to indicate that other approaches may be preferred for frontline treatment in this usually very indolent disease. However, only a very few patients with relapsing/refractory MALT lymphoma have been included in the published clinical trials of bortezomib in indolent lymphomas [38] .
The present study is the first one exploring its activity in a pretreated population with a long disease history, with patients often resistant to the last prior systemic therapy, which would represent the most likely setting for its routine clinical use. The rate and duration of objective responses observed in our study confirm that bortezomib is an active agent in MALT lymphoma. The ORR (48%; 95% CI 29% to 67%) seems lower than the one recently reported in a smaller phase II study by Troch et al. [37] from Austria (81%, 95% CI 54-96%). This difference is very likely due to the different patient selection since our study enrolled pretreated patients all with at least a line of previous systemic chemotherapy and/or rituximab, while in the Austrian trial, 15 of the 16 enrolled patients were chemotherapy naive. The higher dose planned in this study probably has a minor role since most patients had an early dose reduction due to the high rate of neurotoxic adverse events observed.
In our study, response to bortezomib was observed in MALT lymphoma with different primary anatomic sites, with all stages according to Ann Arbor and with different IPI risk. More interestingly, 60% of the patients who were refractory to the last previous systemic therapy had an objective response to bortezomib. Responses also occurred in patients who required dose reductions or who early discontinued the treatment, receiving a lower number of doses than planned, mostly due to the occurrence of adverse events.
The findings of the present study, together with the extremely high remission rate described in untreated patients in the study by Troch et al. [37] , confirm that the inhibition of the proteasome might play a role in the disease control of MALT lymphomas through the inhibition of the NF-jB pathway, as predicted by its peculiar pathogenetic molecular lesions [26, 27] and, perhaps also, by interfering with other intracellular signaling pathways [39] .
However, the relevant proportion of patients who experienced toxic events, mainly neuropathic manifestation (64%; 95% CI 45% to 80%) with a negative impact on quality of life, represents a matter of serious concern in a population of patients with an indolent lymphoma.
Whereas no clear explanation of the high proportion of peripheral neuropathy-described also by other studies and not clearly associated with previous treatments [37] -can be recognized, a solution can be possibly achieved with the adoption of a weekly schedule, suggested to be less toxic [40] .
The potential reduction of the antitumor activity related to a weekly schedule [41] may be counterbalanced by the combination with other active antitumor agents with different toxicity profiles. In this perspective, a number of reports support the safety of bortezomib combined with different agents, including conventional chemotherapeutic drugs [20, 21, 42] and, obviously, monoclonal antibodies [40] . Preclinical data offer interesting perspectives with respect to the combination of bortezomib with different biologic agents [43, 44] . However, only a very few MALT lymphoma patients have been treated in the studies exploring these combinations [40, 42] .
In conclusions, a relevant clinical activity of bortezomib was confirmed in a homogeneous series of pretreated MALT lymphoma patients with relevant representation of adverse prognostic factors. The frequent peripheral neuropathy may, however, reduce the number of patients in whom it can represent a clinically reasonable therapeutic tool. Our findings support the development of novel proteasome inhibitors as well as the exploration of less toxic bortezomib schedules. Further investigations are required in order to identify optimal dose, schedule, and combination regimen. 
